All In Biotech

Drug Trial Radar · NCT06333509

Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL

A Phase 1/2 Open Label Study to Evaluate the Safety and Efficacy of CT071, an Autologous Anti-GPRC5D CAR T, in Relapsed/Refractory Multiple Myeloma (RRMM) or Relapsed/Refractory Primary Plasma Cell Leukemia (RRpPCL)

Last checked: Nov 19, 2026Latest source record: Mar 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

166

Planned (sponsor's estimate)

Start

Apr 15, 2024

Primary completion

Jun 15, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
CARsgen Therapeutics Co., Ltd.Industry
Sponsor type
Industry
First posted
Mar 27, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 1/2 Open label, multicenter, clinical trial of autologous CAR T-cell therapy targeting GPRC5D, in participants with relapsed/refractory multiple myeloma or relapsed/refractory primary plasma cell leukemia.

Conditions

  • Multiple Myeloma
  • Primary Plasma Cell Leukemia

Interventions

  • CT071Biological

    a single CAR-T infusion of CT071

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Evaluation of the Safety of CT071 and determination of Maximum Tolerated Dose (MTD).Time frame: Day 1 - Month 24
  2. Phase 2: Objective response rateTime frame: Day 1 - Month 24

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.